Article Text

PDF
Efficacy and safety of direct-acting antiviral agents when combined with secukinumab
  1. Virginia Martinez-Santana1,
  2. Esther Rodriguez-Murphy1,
  3. Alex Smithson2,
  4. Nuria Miserachs-Aranda1,
  5. Ruben del Río-Gil3,
  6. Inmaculada Torre-Lloverás1
  1. 1Pharmacy, Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain
  2. 2Infectious Diseases Unit, Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain
  3. 3Dermatology, Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain
  1. Correspondence to Dr Virginia Martinez-Santana, Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona, Spain; vmartinez1{at}hotmail.com, vmartins{at}hes.scs.es

Abstract

Background The interference in the immune response induced by biological disease-modifying antirheumatic drugs (bDMARDs) increases the risk of reactivation of infections. Treatment of patients with chronic hepatitis C virus (HCV) infection and psoriasis is complex. The efficacy and safety of the new direct-acting antiviral agents (DAA) when combined with bDMARDs remain unknown.

Case report We present a case of a 44-year-old Caucasian man affected with psoriasis and HCV infection. Throughout the course of the psoriatic disease, this patient received several lines of treatment, including secukinumab, a new type of bDMARD. At the time of commencing secukinumab, new DAA agents (ledipasvir/sofosbuvir) were also initiated. At week 12 post-treatment, hepatitis C viral load was undetectable and the patient remained in remission of psoriasis.

Conclusion This case report suggests that secukinumab is a therapeutic option in patients with psoriasis, particularly in those cases with HCV infection where treatment with DAA agents is warranted.

  • Psoriasis
  • Hepatology
  • PHARMACOTHERAPY
  • CLINICAL PHARMACY
  • VIROLOGY
View Full Text

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.